315 related articles for article (PubMed ID: 16979654)
21. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
22. Structure-based thermodynamic analysis of HIV-1 protease inhibitors.
Bardi JS; Luque I; Freire E
Biochemistry; 1997 Jun; 36(22):6588-96. PubMed ID: 9184138
[TBL] [Abstract][Full Text] [Related]
23. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
[TBL] [Abstract][Full Text] [Related]
24. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
25. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
27. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
28. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis.
Luque I; Todd MJ; Gómez J; Semo N; Freire E
Biochemistry; 1998 Apr; 37(17):5791-7. PubMed ID: 9558312
[TBL] [Abstract][Full Text] [Related]
30. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface.
Bannwarth L; Reboud-Ravaux M
Biochem Soc Trans; 2007 Jun; 35(Pt 3):551-4. PubMed ID: 17511649
[TBL] [Abstract][Full Text] [Related]
31. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
32. Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases.
Bannwarth L; Rose T; Dufau L; Vanderesse R; Dumond J; Jamart-Grégoire B; Pannecouque C; De Clercq E; Reboud-Ravaux M
Biochemistry; 2009 Jan; 48(2):379-87. PubMed ID: 19105629
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 protease folding and the design of drugs which do not create resistance.
Broglia R; Levy Y; Tiana G
Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
[TBL] [Abstract][Full Text] [Related]
35. Computational titration analysis of a multiprotic HIV-1 protease-ligand complex.
Spyrakis F; Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
J Am Chem Soc; 2004 Sep; 126(38):11764-5. PubMed ID: 15382890
[TBL] [Abstract][Full Text] [Related]
36. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
Zhu Z; Schuster DI; Tuckerman ME
Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
[TBL] [Abstract][Full Text] [Related]
38. Oximinoarylsulfonamides as potent HIV protease inhibitors.
Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
40. Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
Frecer V; Miertus S; Tossi A; Romeo D
Drug Des Discov; 1998 Oct; 15(4):211-31. PubMed ID: 10546067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]